Gilead to Pay Up to $282M for Genmab HIV Platform

Source: The Country Caller

Aug 11, 2016

Gilead Sciences has been exclusively granted licensed use of Genmab’s DuoBody technology, in an aim to create a platform for the development of antibodies targeting HIV.

Gilead will pay Denmark-based Genmab $5 million upfront, followed by regulatory and sales milestone up to $277 million for the first product.

The bispecific antibody technology from Genmab uses antibodies to efficiently target disease and cease the bacterial activity. The platform will strengthen Gilead's presence in a growing field of HIV research.

Read the Country Caller Coverage

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments